Enzymatics Overview
- Year Founded
-
2006
- Status
-
Acquired/Merged
- Employees
-
70
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$114M
Enzymatics General Information
Description
Producer of enzymes intended for genomic sequencing machines. The company's products are used by commercial entities engaged in the development, enabling manufacturer with platforms dedicated to nucleic acid identification.
Contact Information
Website
www.enzymatics.comCorporate Office
- 100 Cummings Center
- Suite 407J
- Beverly, MA 01915
- United States
Corporate Office
- 100 Cummings Center
- Suite 407J
- Beverly, MA 01915
- United States
Enzymatics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 16-Dec-2014 | $114M | Completed | Clinical Trials - Phase 1 | ||
| 3. Later Stage VC | 14-Aug-2013 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC | 01-Sep-2006 | $1.6M | $1.8M | Completed | Startup | |
| 1. Seed Round | $200K | $200K | Completed | Startup |
Enzymatics Comparisons
Industry
Financing
Details
Enzymatics Competitors (21)
One of Enzymatics’s 21 competitors is New England Biolabs, a Corporation company based in Ipswich, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| New England Biolabs | Corporation | Ipswich, MA | ||||
| Genetix Biotherapeutics | Private Equity-Backed | Somerville, MA | ||||
| Kanvas | Venture Capital-Backed | Monmouth Junction, NJ | ||||
| Repligen | Corporation | Waltham, MA | ||||
| Condalab | Corporation | Madrid, Spain |
Enzymatics Patents
Enzymatics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20150337364-A1 | Isothermal methods and related compositions for preparing nucleic acids | Inactive | 27-Jan-2014 | ||
| WO-2014071295-A1 | Methods and kits for nucleic acid sample preparation for sequencing | Inactive | 02-Nov-2012 | ||
| AU-2010314980-A1 | Composition and method for synthesizing a deoxyribonucleotide chain using a double stranded nucleic acid complex with a thermostable polymerase | Inactive | 06-Nov-2009 | ||
| CA-2779689-A1 | Composition and method for synthesizing a deoxyribonucleotide chain using a double stranded nucleic acid complex with a thermostable polymerase | Inactive | 06-Nov-2009 | ||
| EP-2496712-A1 | Composition and method for synthesizing a deoxyribonucleotide chain using a double stranded nucleic acid complex with a thermostable polymerase | Inactive | 06-Nov-2009 | C12Q1/6853 |
Enzymatics Signals
Enzymatics Former Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Benevolent Capital | PE/Buyout | Minority | ||
| Keswick Ventures | Venture Capital | Minority | ||
| PBM Capital | PE/Buyout | Minority |
Enzymatics Acquisitions (1)
Enzymatics’s most recent deal was a Merger/Acquisition with ArcherDX for . The deal was made on 06-Sep-2013.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| ArcherDX | 06-Sep-2013 | Merger/Acquisition | Discovery Tools (Healthcare) |
Enzymatics FAQs
-
When was Enzymatics founded?
Enzymatics was founded in 2006.
-
Where is Enzymatics headquartered?
Enzymatics is headquartered in Beverly, MA.
-
What is the size of Enzymatics?
Enzymatics has 70 total employees.
-
What industry is Enzymatics in?
Enzymatics’s primary industry is Biotechnology.
-
Is Enzymatics a private or public company?
Enzymatics is a Private company.
-
What is the current valuation of Enzymatics?
The current valuation of Enzymatics is .
-
What is Enzymatics’s current revenue?
The current revenue for Enzymatics is .
-
How much funding has Enzymatics raised over time?
Enzymatics has raised $5.59M.
-
Who are Enzymatics’s investors?
Benevolent Capital, Keswick Ventures, and PBM Capital have invested in Enzymatics.
-
Who are Enzymatics’s competitors?
New England Biolabs, Genetix Biotherapeutics, Kanvas, Repligen, and Condalab are some of the 21 competitors of Enzymatics.
-
When was Enzymatics acquired?
Enzymatics was acquired on 16-Dec-2014.
-
Who acquired Enzymatics?
Enzymatics was acquired by Qiagen.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process